ClinicalTrials.gg
RecruitingNCT04641247Updated Jun 24, 2026

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

A Phase 2 interventional study of Niraparib in Ovarian Neoplasms and Breast Neoplasms, sponsored by GlaxoSmithKline. Recruiting at 25 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Planned enrollment
25th of 44
37 · median 41
Started
2021
with 4 others
Phase 2
18 of 44
5 open now
Primary completion
2026-12
later than 9 of 13 live
Registered
29th of 44
by date
Lead sponsor
2 of 44
GlaxoSmithKline

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 25th largest by planned enrollment, is one of 5 that started in 2021, is one of 18 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 29th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.

03

Conditions studied

  • Ovarian Neoplasms
  • Breast Neoplasms

Keywords

  • Adverse events
  • Open-label extension
  • Parent study
  • Niraparib
  • Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is able to understand the study procedures and agrees to participate in the study by providing written .
  • Participant is willing and able to comply with scheduled visits, treatment plans, and any other study procedures.
  • Participant is currently receiving treatment with niraparib (as monotherapy or in combination) in a GlaxoSmithKline/TESARO-sponsored study that has fulfilled the requirements for the primary objective.
  • Participant is currently benefiting from treatment with niraparib as assessed by the Investigator according to the parent study protocol requirements.
  • Participants of who are sexually active and their partners must agree to the use of an effective form of throughout their participation during study treatment through 180 days after last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Participant has been permanently discontinued from niraparib treatment in the parent study for any reason.
  • Participant currently has unresolved toxicities for which niraparib dosing has been interrupted in the parent study. Participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow niraparib treatment to resume.
  • Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Participant is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use during niraparib treatment and for 30 days after receiving the final dose of study treatment).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Participants receiving niraparib

    Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.

    Drug: Niraparib

Interventions

  • Niraparib tablets or capsules will be given once a day via the oral route.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)

    AEs, SAEs and AESI will be collected.

    Time frame: Up to 5 years

  2. Number of participants with clinically significant changes in Eastern Co-operative Oncology Group (ECOG) performance status

    The performance status will be assessed using ECOG scale, where Grade 0 (fully active), Grade 1 (restricted in physically strenuous activity), Grade 2 (ambulatory and capable of all self-care), Grade 3 (capable of only limited self-care) and Grade 4 (completely disabled). Number of participants with clinically significant changes in ECOG performance status will be summarized.

    Time frame: Up to 5 years

  3. Number of participants with clinically significant changes in hematology and clinical chemistry parameters

    Blood samples will be collected for the analysis of hematology and clinical chemistry parameters.

    Time frame: Up to 5 years

  4. Number of participants with clinically significant changes in vital signs

    Number of participants with clinically significant changes in vital signs will be assessed.

    Time frame: Up to 5 years

  5. Number of participants with clinically significant changes in physical examination

    Number of participants with clinically significant changes in physical examination will be assessed.

    Time frame: Up to 5 years

  6. Number of participants with use of concomitant medications

    Number of participants using concomitant medications will be assessed.

    Time frame: Up to 5 years

07

Study locations

18 of 25 sites recruiting
  • GSK Investigational Site
    Tucson, Arizona 85710, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Encinitas, California 92024, United States
    Recruiting
  • GSK Investigational Site
    Los Angeles, California 90048, United States
    Recruiting
  • GSK Investigational Site
    Whittier, California 90603, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
    Recruiting
  • GSK Investigational Site
    Harvey, Illinois 60426, United States
    Recruiting
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
    Recruiting
  • GSK Investigational Site
    Grand Rapids, Michigan 60637-1470, United States
    Recruiting
  • GSK Investigational Site
    Morristown, New Jersey 07962-1956, United States
    Recruiting
  • GSK Investigational Site
    Lake Success, New York 11042, United States
    Recruiting
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Graz, A-8036, Austria
    Recruiting
  • GSK Investigational Site
    Vienna, 1090, Austria
    Recruiting
  • GSK Investigational Site
    Kelowna, British Columbia V5Z 4E6, Canada
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • GSK Investigational Site
    Odense C, 5000, Denmark
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Nantes, 44202, France
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Nice, 06189, France
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Haifa, 3109601, Israel
    Recruiting
  • GSK Investigational Site
    Cremona, 26100, Italy
    Recruiting
  • GSK Investigational Site
    Madrid, 28040, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28046, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 68 months is above that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2020
First posted
Nov 23, 2020
StartActual
Apr 16, 2021
Primary completionEst.
Dec 28, 2026
CompletionEst.
Dec 28, 2026
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04641247
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 23, 2020
Start date
Apr 16, 2021
Primary completion
Dec 28, 2026 (estimated)
Completion
Dec 28, 2026 (estimated)
Last update
Jun 24, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion